RxDoctor Payments Data

Sriharsha Athota, MD

Hospitalist · Hattiesburg, MSNPI 1134502115

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $421 and has fallen 72.4% since, to $116 in 2025.

$1,728in general payments, 2019–2025

Across 80 payments — averaging $21.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$264
  • Boehringer Ingelheim$250
  • Gilead$223
  • AbbVie$207
  • AstraZeneca$157
  • E.r. Squibb & Sons, L.L.C.$154
  • plus $473 from 9 others

What the payments were for

  • Food & beverage$1,728100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,728 in reported general payments places this provider in the 85th percentile of 102 hospitalist providers in Mississippi.

See all hospitalist providers in Mississippi

Medicare billing

Part B allowed, 2024
$134,514
Medicare patients
442
Services billed
1,525

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$36,853
EntrestoSacubitril/Valsartan37$27,077
JardianceEmpagliflozin22$15,370
BrilintaTicagrelor15$6,832
Pantoprazole Sodium132$862
Albuterol Sulfate HfaAlbuterol Sulfate18$664
Amiodarone Hcl58$551
Metoprolol Succinate60$476
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav35$465
Furosemide115$417
Atorvastatin Calcium53$278
ClopidogrelClopidogrel Bisulfate36$259
Tamsulosin Hcl30$179
Hydralazine Hcl21$160
Isosorbide Mononitrate ErIsosorbide Mononitrate29$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$117$36,85349 claims
NovartisEntresto$20$27,07737 claims
Boehringer IngelheimJardiance$250$15,37022 claims
AstraZenecaBrilinta$157$6,83215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 102 hospitalist providers in Mississippi.

Other hospitalist in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →